TheraRadar
Data updated: May 26, 2026

ABLYSINOL (dehydrated alcohol)

Cardiovascular Approved 2018-06-21

Ablysinol is a dehydrated alcohol injection used for adults with symptomatic hypertrophic obstructive cardiomyopathy. It helps patients who are not candidates for surgical myectomy by improving their ability to exercise. This medication acts as an ablative agent to create a controlled area of tissue death within the heart's septum.

Source: FDA Label • BPI LABS

How ABLYSINOL Works

This drug works by acting as a tissue toxin when injected through a catheter into a specific septal vessel. This process produces a controlled myocardial infarction, which causes the thickened heart septum to thin.

1
Indication
--
Phase 3 Trials
7
Years on Market

Details

Status
Prescription
First Approved
2018-06-21
Routes
INTRA-ARTERIAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: DEHYDRATED ALCOHOL

ABLYSINOL Approval History

2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
4 FDA actions from 2018 to 2025
Mar 2025 SUPPL
Mfg · Manufacturing (CMC)
Jun 2018 ORIGINAL
Update · Type 5 - New Formulation or New Manufacturer

What ABLYSINOL Treats

1 indications

ABLYSINOL is approved for 1 conditions since its original approval in 2018. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hypertrophic Obstructive Cardiomyopathy
Source: FDA Label

ABLYSINOL Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 7 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to ABLYSINOL

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

DEHYDRATED ALCOHOL
DEHYDRATED ALCOHOL
1 shared
ROYAL PHARMS
Shared indications:
Hypertrophic Obstructive Cardiomyopathy
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT06703437 STUDY-22-00221 Ph 1 active not recruiting Long Acting Neuraxial Peri-prostatic Block in Cancer
NCT02910414 TARGET BP I CR0002 Ph 3 active not recruiting TARGET BP I Clinical Trial
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ABLYSINOL FDA Label Details

Indications & Usage

FDA Label (PDF)

ABLYSINOL is indicated for the treatment of Hypertrophic Obstructive Cardiomyopathy.

Track ABLYSINOL with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.